Trial reportCancer medicine2019
Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.
Trial report in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and Factors Associated With Cancer-Related Fatigue Among Children and Adolescents Undergoing Cancer Treatment: A Systematic Review and Meta-Analysis.Cancer medicine · 2024Pooled it
- Precision-based exercise as a new therapeutic option for children and adolescents with haematological malignancies.Scientific reports · 2020Trial
- Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.Cancer medicine · 2019Trial
- Article
- Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices.Cancer · 2025Review
- Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research.Cancer medicine · 2024Article
- Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.Haematologica · 2023Article
- Article
- Children's Oncology Group's 2023 blueprint for research: Cancer control and supportive care.Pediatric blood & cancer · 2023Article
- Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.Pediatric blood & cancer · 2023Article
- Barriers and Opportunities for Patient-Reported Outcome Implementation: A National Pediatrician Survey in the United States.Children (Basel, Switzerland) · 2022Article
- Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia.JAMA network open · 2021Article
- Treatments for children and adolescents with AML.Blood research · 2020Review
- Profiles of Symptom Suffering and Functioning in Children and Adolescents Receiving Chemotherapy.Cancer nursingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionObjectives were used to describe guardian proxy-report and child self-report quality of life (QoL) during chemotherapy for pediatric acute myeloid leukemia (AML) patients.
methodsPatients enrolled on the phase 3 AML trial AAML1031 who were 2-18 years of age with English-speaking guardians were eligible. Instruments used were the PedsQL Generic Core Scales, Acute Cancer Module, and Multidimensional Fatigue Scale. Assessments were obtained at the beginning of Induction 1 and following completion of cycles 2-4. Potential predictors of QoL included the total number of nonhematological grade 3-4 Common Terminology Criteria for Adverse Event (CTCAE) submissions.
resultsThere were 505 eligible guardians who consented to participate and 348 of their children provided at least one self-report assessment. The number of submitted CTCAE toxicities was significantly associated with worse physical health summary scores (β ± standard error (SE) -3.00 ± 0.69; P < 0.001) and general fatigue (β ± SE -2.50 ± 0.66; P < 0.001). Older age was significantly associated with more fatigue (β ± SE -0.58 ± 0.25; P = 0.022). Gender, white race, Hispanic ethnicity, private insurance status, risk status, bortezomib assignment, and duration of neutropenia were not significantly associated with QoL. DISCUSSION: The number of CTCAE toxicities was the primary factor influencing QoL among children with AML. Reducing toxicities should improve QoL; identifying approaches to ameliorate them should be a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.